Bladder TumourUro-Oncology Unit

Bladder tumours develop from the transitional epithelium or urothelium that covers the inside of the bladder.

Bladder tumours are more frequent in men, and Spain has one of the highest incidences in Europe. Tobacco use is responsible for 50% of cases, increasing the risk by 4 in comparison to non-smoking patients. It also has a relationship with environmental and occupational exposure (aluminium, dyes, paints, oil, rubber, textiles, etc.). Other causes include radiation on the pelvis, parasites (schistosomiasis), drugs such as cyclophosphamide, exposure to trihalomethanes from ingested water etc.

The most frequent symptomatology is haematuria (80-90%), which may be accompanied by clots. Another form of presentation are irritative urinary symptoms (in the absence of urinary tract infection), consisting of increased urination frequency, dysuria or itching and urinary urgency.

Colic pain can also appear, as a consequence of upper urinary tract obstruction, or systemic symptoms in metastatic cases, being rare (weight loss, anorexia, fever etc).

There are two entities with different prognoses and treatments: the non-muscle invasive bladder tumour, which respects the muscle layer of the bladder (75%) and the muscle-invasive bladder tumour which affects the muscle layer (25%). Optimal management of this disease requires an uro-oncology unit capable of treating it in all its stages.